CD79A and cystic fibrosis: The antibody-mediated response against SARS-CoV-2 was evaluated in terms of both neutralizing IgG and IgA antibodies in serum samples collected at T0, T1 and T2 (Figure 1) from 178 patients with CF, including 18 LTR subjects.